Previous close | 115.28 |
Open | 115.35 |
Bid | 114.80 x 900 |
Ask | 114.85 x 800 |
Day's range | 114.79 - 115.59 |
52-week range | 92.19 - 120.92 |
Volume | |
Avg. volume | 1,251,141 |
Market cap | 232.533B |
Beta (5Y monthly) | 0.50 |
PE ratio (TTM) | 23.49 |
EPS (TTM) | 4.89 |
Earnings date | 29 Oct 2024 |
Forward dividend & yield | 3.78 (3.28%) |
Ex-dividend date | 07 Mar 2024 |
1y target est | 115.46 |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.
IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.